Posted by Michael Wonder on 12 May 2021
Evofem Biosciences receives fast track designation for EVO100 for prevention of gonorrhoea in women
12 May 2021 - Potential for expedited NDA review of EVO100 by FDA.
Evofem Biosciences today announced that the U.S. FDA has granted fast track designation for EVO100 for the prevention of urogenital gonorrhoea in women.
